Search

Background: In Sjogren’s Syndrome (SS), ocular damage is mediated by inflammation induced by antibodies, enzymes, and other effectors that could be used as clinical indicators of the ocular surface damage. There is evidence suggesting that increased activity of matrix metalloproteinases (MMPs) is corelated with an increased ocular damage because of its potential inflamatory activity and could be used as a potential therapeutic target for dry eye1,2. Very few studies have addressed the rol betwen the ocular MMPS and the clinical parameters of SS. Objectives: To determine the level of correlation between the serological profile of autoantibodies with ophthalmological parameters at the cornea level. Methods: Cross-sectional, observational, and descriptive study. Sixty patients with a diagnosis of primary Sjogren’s syndrome (pSS) classified according to the ACR/EULAR 2016 criteria were included. The following measurements were made: Schirmer test, lacrimal osmolarity, ocular staining score (OSS), and ocular surface disease index (OSDI) and metalloproteinase-9 (MMP-9) in tear and antibodies were measured in peripheral blood serum: RF isotypes (IgA, IgG, IgM), anti-SSA/Ro and anti-SSB/La in. Results: Fifty-eight women participated (96.7%) with an average age of 53 years (± 13.01) (Table 1). We found a positive correlation between OSS and RF-IgM (rho=0.385 P=0.002), RF-IgA (rho=0.256 P=0.049), and anti-Ro/SSA (rho=0.302 P Conclusion: A significant correlation was observed between serology, ocular surface damage (OSS), and ocular surface inflammation (MMP-9). The positivity of RF isotypes IgM and IgA could alert the clinician about the ocular damage to initiate a study directed to this organ. Nevertheless this present study shows preeliminary outcomes, we need to enroll more patients to obtain better outcomes. References: [1] Aluri, H. S., et al. (2015). Role of Matrix Metalloproteinases 2 and 9 in Lacrimal Gland Disease in Animal Models of Sjogren’s Syndrome. Investigative ophthalmology & visual science, 56(9), 5218-28. [2] Messmer, E. M., et al. (2016). Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. Ophthalmology, 123(11), 2300–2308. https://doi.org/10.1016/j.ophtha.2016.07.028. Disclosure of Interests: None declared

Background: Primary Sjogren’s syndrome (pSS) has several classification criteria, whose diagnostic performances vary depending on the studied population1. Concordance and differences among these criterias should be evaluated for independent populations to determine the diagnostic performance. Objectives: To compare the performance among 3 classification criteria for pSS and determine the level of concordance among them. Methods: Descriptive, retrospective, and cross-sectional study including 172 patients from the Rheumatology Service of the Hospital Universitario ”Dr. Jose Eleuterio Gonzalez”, who were studied for dry syndrome. The clinical criterion of the attending physician was considered as the gold standard for diagnosis. Different parameters were collected: presence of xerostomia, xerophthalmia, Schirmer’s test, sialometry, ocular staining, ANA, anti-Ro/SSA and anti-La/SSB antibodies, RF isotypes (IgA, IgM, IgG), and focal lymphocytic infiltrate in minor salivary gland biopsy. The criteria proposed by the American European Consensus Group (AECG), ACR and, ACR/EULAR were used to evaluate the classification. Compliance was determined for each set of criteria. Results: Sociodemographic characteristics and clinical manifestations are shown in Table 1. For the AECG, ACR, and ACR/EULAR criteria, the sensitivity was 89.1%, 98.9% and 88% and the specificity was 93.8%, 71.3%, and 96.3%, respectively (Table 2). The ACR/EULAR criteria have an adequate level of agreement (k=0.663, P AECG: American European Consensus Group criteria; Conclusion: In our population, the ACR criteria showed the highest sensitivity, while the ACR/EULAR criteria showed the highest specificity, showing a moderate level of agreement. Despite the validation of these criteria, its application in real life tests its performance according to the population studied. References: [1] Tsuboi, H., et al. (2017). Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjogren’s syndrome with other sets of criteria in Japanese patients. Annals of the Rheumatic Diseases, 76(12), 1980?1985. https://doi.org/10.1136/annrheumdis-2016-210758. Disclosure of Interests: None declared